Latest Development Pipeline News

Page 3 of 32
Dexus has announced a new on-market buyback of up to 10% of its securities, aiming to address the disconnect between its market valuation and underlying asset values while maintaining capital discipline.
Eva Park
Eva Park
18 Feb 2026
Dexus has reported a strong half-year result with a $348.5 million profit turnaround, robust leasing growth, and strategic capital moves including a $950 million equity raise and a 10% on-market buyback.
Eva Park
Eva Park
18 Feb 2026
Vicinity Centres reported a strong first half of FY26, boosting profits and advancing key retail and mixed-use developments, while maintaining a conservative balance sheet.
Eva Park
Eva Park
18 Feb 2026
Mirvac Group reported a robust half-year result with a 5% rise in operating profit and a significant boost in residential sales, underpinned by a $1 billion joint venture with Mitsubishi Estate. The company’s strategic pipeline restocking and strong leasing performance signal promising growth ahead.
Eva Park
Eva Park
18 Feb 2026
HealthCo Healthcare & Wellness REIT reported resilient 1H FY26 results despite suspending distributions amid ongoing Healthscope challenges, underpinned by a diversified $1.4 billion healthcare real estate portfolio and strategic lease agreements.
Eva Park
Eva Park
17 Feb 2026
Abacus Storage King has reported a 4.8% increase in statutory net profit to $71.1 million for the half-year ended December 2025, alongside a $3.7 billion asset base and plans to potentially internalise management functions.
Eva Park
Eva Park
16 Feb 2026
Contact Energy has announced a $525 million equity raise to accelerate its renewable energy projects, following a strong first half of FY26 with significant profit growth and strategic acquisitions.
Maxwell Dee
Maxwell Dee
16 Feb 2026
Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.
Ada Torres
Ada Torres
12 Feb 2026
Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.
Victor Sage
Victor Sage
11 Feb 2026
Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.
Ada Torres
Ada Torres
11 Feb 2026
Dexus Industria REIT (DXI) reported robust half-year results with 7.4% like-for-like income growth and near full occupancy, upgrading its FY26 FFO guidance. The REIT is actively recycling capital and progressing a $225 million development pipeline focused on high-quality industrial assets.
Eva Park
Eva Park
11 Feb 2026
Dexus Industria REIT has slightly upgraded its FY26 funds from operations guidance, driven by robust portfolio income growth and strategic acquisitions in key industrial hubs. The REIT’s active management and development pipeline underpin its confidence in delivering secure, growing income.
Eva Park
Eva Park
11 Feb 2026